- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04978662
Sleep and Chronotype in Children With Type 1 Diabetes
Determination of Sleep Disorder and Chronotype in Children and Adolescents With Type 1 Diabetes; Observation of the Impact on Glycemic Control and Treatment
Type 1 diabetes is the most common metabolic disorder in children and adolescents. Sleep is important for prognosis and several sleep parameters are related to metabolic control. However, limited number of studies in children and adolescents showed mixed results and recommendations about how to address sleep in the clinical care of diabetes in children are still lacking. There is a need to examine the potential role of sleep in developing preventive interventions for diabetes management in children and adolescents.
The authors aimed to describe sleep/wake patterns ,sleep problems, and chronotype of children and adolescents with type 1 diabetes, and to assess the relation of sleep measures with metabolic control and treatment.
The study has a prospective observational cross-sectional design. An estimated sample size is calculated as 83. Children diagnosed with type 1 diabetes between 6 to 18 years of age will be recruited from two pediatric endocrinology centers specialized in diabetes. Sleep/wake pattern will be assessed by actigraphy, and sleep diaries. Sleep disorder will be assessed by the Diagnostic and Statistical Manual for Mental Disorders (DSM-5) Sleep Disorder Scale, and Chronotype Questionnaire will be used to determine the chronotype.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Type 1 diabetes is the most common metabolic disorder in children and adolescents. Sleep is important for prognosis and several sleep parameters are related to metabolic control. However, limited number of studies in children and adolescents showed mixed results and recommendations about how to address sleep in the clinical care of diabetes in children are still lacking. There is a need to examine the potential role of sleep in preventive interventions.
The authors aimed to describe sleep/wake patterns ,sleep problems, and chronotype of children and adolescents with type 1 diabetes, and to assess the relation of sleep measures with metabolic control and treatment.
The study has a prospective observational cross-sectional design. An estimated sample size is calculated as 83. Children diagnosed with type 1 diabetes between 6 to 18 years of age will be recruited from two pediatric endocrinology centers specialized in diabetes. Sleep/wake pattern will be assessed by actigraphy, and sleep diaries. Sleep wake patterns will be assessed by Philips Respironics Mini-Mitter Actiwatch-2 for at least 3 days at home environment and sleep diaries within 5-minute intervals will be filled out by parents. Actigraphy is a validated wristwatch-like device that distinguishes sleep from wakefulness based on accelerometer measured movement.
Sleep disorder will be assessed by the Diagnostic and Statistical Manual for Mental Disorders (DSM-5) Sleep Disorder Scale, and Chronotype Questionnaire will be used to determine the chronotype.
For metabolic control, targeted standard values will be used for continuous glucose measurement. (Target daily blood glucose ranges 70-180 mg/dl, <4% <70 mg/dl, <1% <54 mg/dl, <25% >180 mg/dl, <5% rate >250 mg/dl). The latest Hemoglobin A1c level will also be evaluated.
A questionnaire developed by the investigators including sociodemographic characteristics, and diabetes related information will be gathered from the patient records.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
-
Istanbul, Kalkun
- Marmara University School of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- aged between 6 to 18 years
- use of continuous glucose monitoring system
Exclusion Criteria:
- acute medical condition that can impact sleep (diabetes keto acidosis, cold, influenza)
- diagnosed neurodevelopmental or behavioral condition like autism spectrum disorder or Attention Deficit/Hyperactivity Disorder
- diagnosed sleep disorder (Obstructive Sleep Apnea)
- Current use of medications that can impact sleep (diphenhydramine)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
sleep wake patterns measured by actigraphy
Tidsramme: baseline
|
sleep wake patterns
|
baseline
|
sleep disorder
Tidsramme: Baseline
|
sleep disorder measured with the Diagnostic and Statistical Manual for Mental Disorders (DSM-5) Sleep Disorder Scale.
The scale has an 8-item parent form, that could be filled up by parents or legal guardians of children aged between 6-17 years, and a 9-item self report form to be filled up by adolescents aged between 11-17 years.
For each item, the caregiver is asked to rate the severity of symptoms related to sleep disorders that occurred within the past 7 days, she/he had observed in his/her child.
The scale has a 5-point Likert type rating (1=never, 2=very little/rarely, 3=sometimes, 4=most of the time, 5=almost all the time).
Total scores range between 8-40 and higher scores indicate presence of much more severe sleep-related problems.
|
Baseline
|
chronotype
Tidsramme: baseline
|
chronotype measured with Chronotype Questionnaire.Children's Chronotype Questionnaire (CCTQ) is a parent report, 27-item mixed format questionnaire measuring chronotype of children in multiple domains : the midsleep point on free days (MSF), a morningness/eveningness scale(M/E) score, and a five-point chronotype (CT) score.
|
baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
metabolic control
Tidsramme: baseline
|
metabolic control measured by number of hypo and hyperglycemic episodes over the past month
|
baseline
|
metabolic control
Tidsramme: baseline
|
metabolic control measured by the most recent hemoglobin A1c
|
baseline
|
treatment
Tidsramme: baseline
|
treatment measured by insulin dose per kilogram
|
baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 120S789
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAfsluttetType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | IDDMForenede Stater, Australien
-
Capillary Biomedical, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, insulinafhængig, 1Australien
-
Spiden AGDCB Research AGRekrutteringType 1 diabetes mellitus | Type 1 diabetes mellitus med hypoglykæmi | Type 1 diabetes mellitus med hyperglykæmiSchweiz
-
Capillary Biomedical, Inc.AfsluttetType 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, type I | Diabetes mellitus, insulinafhængig, 1 | IDDMØstrig
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute...UkendtType 1 diabetes mellitus med hyperglykæmi | Type 1 diabetes mellitus med hypoglykæmiPolen
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AfsluttetType 1 diabetes mellitus | T1DM | T1D | Nyopstået type 1-diabetes mellitusForenede Stater, Australien
-
National Institute of Diabetes and Digestive and...AfsluttetDiabetes mellitus type 1Forenede Stater
-
Stem Cells ArabiaAfsluttetGlukosemetabolismeforstyrrelser | Metaboliske sygdomme | Sygdomme i immunsystemet | Autoimmune sygdomme | Sygdomme i det endokrine system | Diabetes mellitus type 1Jordan
-
Shanghai Changzheng HospitalRekrutteringSkør type 1 diabetes mellitusKina